Attorney Generals Of Several States Warn CVS, Walgreens Against Mailing Abortion Medication
Republican attorneys general in 20 states warned CVS Health Corp (NYSE: CVS) and Walgreens Boots Alliance Inc (NASDAQ: WBA) against mailing abortion pills in their jurisdictions.
Also Read: Walgreens Boots Alliance Might Be First Pharmacy To Dispense Abortion Pills, Others To Follow.
“We emphasize that it is our responsibility as State Attorneys General to uphold the law and protect the health, safety, and well-being of women and unborn children in our states,” the attorney generals said in letters to the nation’s two largest drugstore chains.
“Part of that responsibility includes ensuring that companies like yours are fully informed of the law so that harm does not come to our citizens,” they warned.
The FDA approved mifepristone more than 20 years ago.
Last month, the FDA said it would allow pharmacies to offer abortion pills in the U.S., with pharmacies must complete a form for certification to distribute the abortion pills.
The pill, mifepristone, has become a central focus after the Supreme Court’s decision last June to overturn Roe v. Wade, which protected access to an abortion procedure as a constitutional right for 50 years.
The Biden administration last month issued a legal opinion arguing that the Postal Service can mail the pill to states where it is banned if the sender does not intend to break the law, CNBC reported.
The Justice Department argued that even in states with severe restrictions on abortion, there are exceptions where mifepristone would be legal.
But the attorneys general dismissed the Justice Department opinion as “bizarre” and said they expect the courts to uphold their view that mifepristone cannot be sent by mail in their states.
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
This article Attorney Generals Of Several States Warn CVS, Walgreens Against Mailing Abortion Medication originally appeared on Benzinga.com
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.